Current Price Disclosure cycle – 2024 April

Page last updated: 28 March 2024

The 2024 April cycle has a data collection period of 1 April 2023 to 30 September 2023.

Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 13 November 2023.

The reduction day is 1 April 2024.

Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.

Contents

Outcomes of Price Disclosure calculations

The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health and Aged Care. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes reflecting these determinations have been published in a legal determination on the Federal Register of Legislation website.  Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2023 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2023 will also take the reduction on 1 April 2024 under section 99ADHA of the Act.

Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 11 January 2024.

A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.

Legal Instrument Drug

Legal Instrument Form

Legal Instrument MoA

Brands of PI designated brands under 99ADHC (Y/N)

Floor Price

Price reduction applied in 2 previous cycles (Y/N?)

Average UPR exceeds 12.5% over 3 cycles (Y/N)

Oct-23 AEMP

Apr-24 AEMP

Percentage difference between Oct-23 and Apr-24 AEMP (%)

UPR threshold (%)

Calculations based on:
OWAPD = all brand data
GWAPD = originator brand data removed

adalimumab

Injection 20 mg in 0.4 mL pre-filled syringe

Injection

N

-

-

-

380.99

311.46

18.25%

10%

GWAPD

adalimumab

Injection 40 mg in 0.4 mL pre-filled pen

Injection

N

-

-

-

618.9

505.95

18.25%

10%

GWAPD

adalimumab

Injection 40 mg in 0.8 mL pre-filled pen

Injection

N

-

-

-

761.98

622.92

18.25%

10%

GWAPD

adalimumab

Injection 40 mg in 0.8 mL pre-filled syringe

Injection

N

-

-

-

761.98

622.92

18.25%

10%

GWAPD

amiodarone

Tablet containing amiodarone hydrochloride 200 mg

Oral

Y

5.98

N

Y

5.98

4.73

20.90%

10%

GWAPD

anastrozole

Tablet 1 mg

Oral

Y

9.24

N

Y

9.24

7.26

21.43%

10%

GWAPD

aprepitant

Capsule 165 mg

Oral

N

-

-

-

62.3

55.17

11.44%

10%

OWAPD

aripiprazole

Tablet 10 mg

Oral

Y

42.28

N

Y

42.28

28.47

32.66%

30%

GWAPD

aripiprazole

Tablet 15 mg

Oral

Y

60

N

Y

60

40.4

32.67%

30%

GWAPD

aripiprazole

Tablet 20 mg

Oral

Y

73.04

N

Y

73.04

49.18

32.67%

30%

GWAPD

aripiprazole

Tablet 30 mg

Oral

Y

89.01

N

Y

89.01

59.93

32.67%

30%

GWAPD

bevacizumab

Solution for I.V. infusion 100 mg in 4 mL

Injection

N

-

-

-

122

90.32

25.97%

10%

OWAPD

bevacizumab

Solution for I.V. infusion 400 mg in 16 mL

Injection

N

-

-

-

488

361.27

25.97%

10%

OWAPD

bortezomib

Powder for injection 2.5 mg

Injection

N

-

-

-

187.52

55.34

70.49%

10%

OWAPD

bortezomib

Powder for injection 3.5 mg

Injection

N

-

-

-

262.52

77.47

70.49%

10%

OWAPD

bortezomib

Solution for injection 2.5 mg in 1 mL

Injection

N

-

-

-

187.52

55.34

70.49%

10%

OWAPD

bortezomib

Solution for injection 3.5 mg in 1.4 mL

Injection

N

-

-

-

262.52

77.47

70.49%

10%

OWAPD

bosentan

Tablet 125 mg (as monohydrate)

Oral

Y

290.5

N

Y

290.5

169.3

41.72%

30%

GWAPD

bosentan

Tablet 62.5 mg (as monohydrate)

Oral

Y

290.5

N

Y

290.5

169.3

41.72%

30%

GWAPD

buprenorphine

Transdermal patch 10 mg

Transdermal

N

-

-

-

15.45

12.62

18.32%

10%

GWAPD

buprenorphine

Transdermal patch 15 mg

Transdermal

N

-

-

-

19.64

16.04

18.33%

10%

GWAPD

buprenorphine

Transdermal patch 20 mg

Transdermal

N

-

-

-

23.84

19.47

18.33%

10%

GWAPD

buprenorphine

Transdermal patch 25 mg

Transdermal

N

-

-

-

27.81

22.71

18.34%

10%

GWAPD

buprenorphine

Transdermal patch 30 mg

Transdermal

N

-

-

-

31.78

25.95

18.34%

10%

GWAPD

buprenorphine

Transdermal patch 40 mg

Transdermal

N

-

-

-

39.73

32.45

18.32%

10%

GWAPD

buprenorphine

Transdermal patch 5 mg

Transdermal

N

-

-

-

8.58

7.01

18.30%

10%

GWAPD

cabazitaxel

Concentrated injection 60 mg in 1.5 mL, with diluent

Injection

N

-

-

-

178.77

88.67

50.40%

10%

OWAPD

cabazitaxel

Solution concentrate for I.V. infusion 60 mg in 3 mL

Injection

N

-

-

-

152.53

88.67

41.87%

10%

OWAPD

cabazitaxel

Solution concentrate for I.V. infusion 60 mg in 6 mL

Injection

N

-

-

-

152.53

88.67

41.87%

10%

OWAPD

ciclosporin

Capsule 100 mg

Oral

Y

122.35

N

Y

122.35

93.45

23.62%

10%

GWAPD

ciclosporin

Capsule 25 mg

Oral

Y

28.86

N

Y

28.86

22.04

23.63%

10%

GWAPD

ciclosporin

Capsule 50 mg

Oral

Y

60.05

N

Y

60.05

45.87

23.61%

10%

GWAPD

cinacalcet

Tablet 30 mg (as hydrochloride)

Oral

N

-

-

-

27.95

23.72

15.13%

10%

OWAPD

cinacalcet

Tablet 60 mg (as hydrochloride)

Oral

N

-

-

-

55.91

47.44

15.15%

10%

OWAPD

cinacalcet

Tablet 90 mg (as hydrochloride)

Oral

N

-

-

-

83.86

71.16

15.14%

10%

OWAPD

clindamycin

Capsule 150 mg (as hydrochloride)

Oral

Y

5.15

N

Y

5.15

4.17

19.03%

10%

GWAPD

dasatinib

Tablet 100 mg

Oral

N

-

-

-

2050.27

1770.45

13.65%

10%

OWAPD

dasatinib

Tablet 20 mg

Oral

N

-

-

-

1244.78

1074.89

13.65%

10%

OWAPD

dasatinib

Tablet 50 mg

Oral

N

-

-

-

2050.27

1770.45

13.65%

10%

OWAPD

dasatinib

Tablet 70 mg

Oral

N

-

-

-

2538.37

2191.93

13.65%

10%

OWAPD

deferasirox

Tablet 180 mg

Oral

N

-

-

-

92.85

60.54

34.80%

10%

OWAPD

deferasirox

Tablet 360 mg

Oral

N

-

-

-

185.69

121.09

34.79%

10%

OWAPD

deferasirox

Tablet 90 mg

Oral

N

-

-

-

46.43

30.27

34.81%

10%

OWAPD

dimethyl fumarate

Capsule (modified release) 120 mg

Oral

N

-

-

-

173.59

154.25

11.14%

10%

OWAPD

donepezil

Tablet containing donepezil hydrochloride 10 mg

Oral

Y

7.44

N

Y

7.44

5.46

26.61%

10%

GWAPD

donepezil

Tablet containing donepezil hydrochloride 5 mg

Oral

Y

7.44

N

Y

7.44

5.46

26.61%

10%

GWAPD

dorzolamide

Eye drops 20 mg (as hydrochloride) per mL, 5 mL

Application to the eye

Y

6.25

N

Y

6.25

4.93

21.12%

10%

GWAPD

duloxetine

Capsule 60 mg (as hydrochloride)

Oral

Y

4.38

N

Y

4.38

4

25.11%

10%

GWAPD

entecavir

Tablet 0.5 mg (as monohydrate)

Oral

Y

45.78

N

Y

45.78

34.14

25.43%

10%

OWAPD

entecavir

Tablet 1 mg (as monohydrate)

Oral

Y

74.44

N

Y

74.44

55.52

25.42%

10%

OWAPD

erlotinib

Tablet 100 mg (as hydrochloride)

Oral

N

-

-

-

531.47

460.68

13.32%

10%

OWAPD

erlotinib

Tablet 150 mg (as hydrochloride)

Oral

N

-

-

-

657.49

569.91

13.32%

10%

OWAPD

erlotinib

Tablet 25 mg (as hydrochloride)

Oral

N

-

-

-

146.43

126.93

13.32%

10%

OWAPD

ezetimibe with simvastatin

Tablet 10 mg-10 mg

Oral

Y

9.32

N

Y

9.32

7.76

16.74%

10%

GWAPD

ezetimibe with simvastatin

Tablet 10 mg-20 mg

Oral

Y

9.79

N

Y

9.79

8.15

16.75%

10%

GWAPD

ezetimibe with simvastatin

Tablet 10 mg-40 mg

Oral

Y

10.45

N

Y

10.45

8.7

16.75%

10%

GWAPD

ezetimibe with simvastatin

Tablet 10 mg-80 mg

Oral

Y

11.38

N

Y

11.38

9.47

16.78%

10%

GWAPD

fentanyl

Transdermal patch 1.28 mg

Transdermal

Y

6.37

N

Y

6.37

4.81

24.49%

10%

GWAPD

fentanyl

Transdermal patch 10.20 mg

Transdermal

Y

25.31

N

Y

25.31

19.11

24.50%

10%

GWAPD

fentanyl

Transdermal patch 12.375 mg

Transdermal

Y

25.21

N

Y

25.21

19.04

24.47%

10%

GWAPD

fentanyl

Transdermal patch 12.6 mg

Transdermal

Y

20.4

N

Y

20.4

15.4

24.51%

10%

GWAPD

fentanyl

Transdermal patch 16.8 mg

Transdermal

Y

25.31

N

Y

25.31

19.11

24.50%

10%

GWAPD

fentanyl

Transdermal patch 2.063 mg

Transdermal

Y

7.87

N

Y

7.87

5.94

24.52%

10%

GWAPD

fentanyl

Transdermal patch 2.1 mg

Transdermal

Y

6.37

N

Y

6.37

4.81

24.49%

10%

GWAPD

fentanyl

Transdermal patch 2.55 mg

Transdermal

Y

8.1

N

Y

8.1

6.12

24.44%

10%

GWAPD

fentanyl

Transdermal patch 4.125 mg

Transdermal

Y

10.01

N

Y

10.01

7.56

24.48%

10%

GWAPD

fentanyl

Transdermal patch 4.2 mg

Transdermal

Y

8.1

N

Y

8.1

6.12

24.44%

10%

GWAPD

fentanyl

Transdermal patch 5.10 mg

Transdermal

Y

14.89

N

Y

14.89

11.24

24.51%

10%

GWAPD

fentanyl

Transdermal patch 7.65 mg

Transdermal

Y

20.4

N

Y

20.4

15.4

24.51%

10%

GWAPD

fentanyl

Transdermal patch 8.25 mg

Transdermal

Y

18.4

N

Y

18.4

13.89

24.51%

10%

GWAPD

fentanyl

Transdermal patch 8.4 mg

Transdermal

Y

14.89

N

Y

14.89

11.24

24.51%

10%

GWAPD

fluconazole

Capsule 100 mg

Oral

Y

15.47

N

Y

15.47

11.53

25.47%

10%

GWAPD

fluconazole

Capsule 200 mg

Oral

Y

30.14

N

Y

30.14

22.47

25.45%

10%

GWAPD

fluconazole

Capsule 50 mg

Oral

Y

7.95

N

Y

7.95

5.93

25.41%

10%

GWAPD

fluorouracil

Injection 2500 mg in 50 mL

Injection

Y

12.11

N

Y

12.11

9.96

17.75%

10%

OWAPD

fluorouracil

Injection 5000 mg in 100 mL

Injection

Y

24.22

N

Y

24.22

19.92

17.75%

10%

OWAPD

gliclazide

Tablet 30 mg (modified release)

Oral

N

-

-

-

5.61

4.91

12.48%

10%

GWAPD

gliclazide

Tablet 60 mg (modified release)

Oral

N

-

-

-

4.48

3.92

12.50%

10%

GWAPD

gliclazide

Tablet 80 mg

Oral

N

-

-

-

5.45

4.77

12.48%

10%

GWAPD

hydromorphone

Injection containing hydromorphone hydrochloride 10 mg in 1 mL

Injection

N

-

-

-

8.81

7.52

14.64%

10%

GWAPD

hydromorphone

Injection containing hydromorphone hydrochloride 2 mg in 1 mL

Injection

N

-

-

-

6.6

5.64

14.55%

10%

GWAPD

imatinib

Capsule 100 mg (as mesilate)

Oral

Y

209.62

Y

Y

209.62

124.56

40.58%

30%

GWAPD

imatinib

Capsule 400 mg (as mesilate)

Oral

Y

419.23

Y

Y

419.23

249.11

40.58%

30%

GWAPD

imatinib

Tablet 100 mg (as mesilate)

Oral

Y

209.62

Y

Y

209.62

124.56

40.58%

30%

GWAPD

imatinib

Tablet 400 mg (as mesilate)

Oral

Y

419.23

Y

Y

419.23

249.11

40.58%

30%

GWAPD

indapamide

Tablet containing indapamide hemihydrate 2.5 mg

Oral

Y

4.91

N

Y

4.91

4.14

15.68%

10%

GWAPD

infliximab

Powder for I.V. infusion 100 mg

Injection

Y

253.52

N

Y

253.52

186.16

26.57%

10%

GWAPD

lamotrigine

Tablet 100 mg

Oral

Y

11.79

N

Y

11.79

9.13

22.56%

10%

GWAPD

lamotrigine

Tablet 200 mg

Oral

Y

19.82

N

Y

19.82

15.35

22.55%

10%

GWAPD

lamotrigine

Tablet 25 mg

Oral

Y

4.25

N

Y

4.25

4

22.59%

10%

GWAPD

lamotrigine

Tablet 50 mg

Oral

Y

7.08

N

Y

7.08

5.48

22.60%

10%

GWAPD

latanoprost

Eye drops 50 micrograms per mL, 2.5 mL

Application to the eye

Y

4.14

N

Y

4.14

4

29.71%

10%

GWAPD

leflunomide

Tablet 10 mg

Oral

Y

15.3

N

Y

15.3

11.88

22.35%

10%

GWAPD

leflunomide

Tablet 20 mg

Oral

Y

23.3

N

Y

23.3

18.09

22.36%

10%

GWAPD

lenalidomide

Capsule 10 mg

Oral

N

-

-

-

1014.2

886.72

12.57%

10%

OWAPD

lenalidomide

Capsule 15 mg

Oral

N

-

-

-

1221.5

1067.96

12.57%

10%

OWAPD

lenalidomide

Capsule 25 mg

Oral

N

-

-

-

1598.14

1397.25

12.57%

10%

OWAPD

lenalidomide

Capsule 5 mg

Oral

N

-

-

-

774.17

676.86

12.57%

10%

OWAPD

letrozole

Tablet 2.5 mg

Oral

Y

13.88

N

Y

13.88

9.72

29.97%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 100 mg-25 mg (as monohydrate)-200 mg

Oral

N

-

-

-

84.34

67.44

20.04%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 125 mg-31.25 mg (as monohydrate)-200 mg

Oral

N

-

-

-

87.54

70

20.04%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 150 mg-37.5 mg (as monohydrate)-200 mg

Oral

N

-

-

-

92.32

73.82

20.04%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 200 mg-50 mg (as monohydrate)-200 mg

Oral

N

-

-

-

99.66

79.69

20.04%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 50 mg-12.5 mg (as monohydrate)-200 mg

Oral

N

-

-

-

76.36

61.06

20.04%

10%

GWAPD

levodopa with carbidopa and entacapone

Tablet 75 mg-18.75 mg (as monohydrate)-200 mg

Oral

N

-

-

-

79.87

63.86

20.05%

10%

GWAPD

levonorgestrel with ethinylestradiol

Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets

Oral

Y

4.75

N

Y

4.75

4

19.58%

10%

GWAPD

lurasidone

Tablet containing lurasidone hydrochloride 40 mg

Oral

N

-

-

-

27.48

18.99

30.90%

10%

GWAPD

lurasidone

Tablet containing lurasidone hydrochloride 80 mg

Oral

N

-

-

-

54.96

37.97

30.91%

10%

GWAPD

metformin

Tablet (extended release) containing metformin hydrochloride 1 g

Oral

Y

4.01

N

Y

4.01

4

14.96%

10%

GWAPD

metformin

Tablet (extended release) containing metformin hydrochloride 500 mg

Oral

Y

4.01

N

Y

4.01

4

14.96%

10%

GWAPD

metformin

Tablet containing metformin hydrochloride 1 g

Oral

Y

4.36

N

Y

4.36

4

14.91%

10%

GWAPD

metoprolol succinate

Tablet 190 mg (controlled release)

Oral

Y

33.83

N

Y

33.83

26.47

21.76%

10%

GWAPD

metoprolol succinate

Tablet 23.75 mg (controlled release)

Oral

Y

4.59

N

Y

4.59

4

21.79%

10%

GWAPD

metoprolol succinate

Tablet 47.5 mg (controlled release)

Oral

Y

21.66

N

Y

21.66

16.94

21.79%

10%

GWAPD

metoprolol succinate

Tablet 95 mg (controlled release)

Oral

Y

27.06

N

Y

27.06

21.17

21.77%

10%

GWAPD

moclobemide

Tablet 150 mg

Oral

Y

7.79

N

Y

7.79

6.14

21.18%

10%

GWAPD

moclobemide

Tablet 300 mg

Oral

Y

13

N

Y

13

10.24

21.23%

10%

GWAPD

modafinil

Tablet 100 mg

Oral

Y

72.13

N

Y

72.13

55.6

22.92%

10%

GWAPD

montelukast

Tablet, chewable, 4 mg (as sodium)

Oral

Y

5.49

N

Y

5.49

4.09

25.50%

10%

OWAPD

montelukast

Tablet, chewable, 5 mg (as sodium)

Oral

Y

5.17

N

Y

5.17

4

25.53%

10%

OWAPD

mycophenolic acid

Capsule containing mycophenolate mofetil 250 mg

Oral

Y

16.38

N

Y

16.38

12.74

22.22%

10%

GWAPD

mycophenolic acid

Tablet containing mycophenolate mofetil 500 mg

Oral

Y

32.74

N

Y

32.74

25.46

22.24%

10%

GWAPD

nebivolol

Tablet 1.25 mg (as hydrochloride)

Oral

N

-

-

-

11.76

9.78

16.84%

10%

GWAPD

nebivolol

Tablet 10 mg (as hydrochloride)

Oral

N

-

-

-

33.19

27.6

16.84%

10%

GWAPD

nebivolol

Tablet 5 mg (as hydrochloride)

Oral

N

-

-

-

29.37

24.42

16.85%

10%

GWAPD

nicorandil

Tablets 10 mg, 60

Oral

Y

9.51

N

Y

9.51

8.07

15.14%

10%

GWAPD

nicorandil

Tablets 20 mg, 60

Oral

Y

13.25

N

Y

13.25

11.24

15.17%

10%

GWAPD

olmesartan

Tablet containing olmesartan medoxomil 40 mg

Oral

Y

6.95

N

Y

6.95

5.67

18.42%

10%

GWAPD

olmesartan with hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg

Oral

Y

8.04

N

Y

8.04

6.2

22.89%

10%

GWAPD

olmesartan with hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg

Oral

Y

7.11

N

Y

7.11

5.49

22.78%

10%

GWAPD

palonosetron

Injection 250 micrograms (as hydrochloride) in 5 mL

Injection

N

-

-

-

22.04

9.91

55.04%

10%

OWAPD

paraffin

Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer-188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free)

Application to the eye

N

-

-

-

23.8

20.78

12.69%

10%

OWAPD

paraffin

Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g

Application to the eye

N

-

-

-

4.1

3.58

12.68%

10%

OWAPD

paraffin

Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g

Application to the eye

N

-

-

-

7.86

6.86

12.72%

10%

OWAPD

riluzole

Tablet 50 mg

Oral

Y

148.07

N

Y

148.07

113.3

23.48%

10%

GWAPD

risperidone

Tablet 1 mg

Oral

Y

4.7

N

Y

4.7

4

17.23%

10%

GWAPD

risperidone

Tablet 2 mg

Oral

Y

10.74

N

Y

10.74

8.9

17.13%

10%

GWAPD

risperidone

Tablet 3 mg

Oral

Y

16.57

N

Y

16.57

13.73

17.14%

10%

GWAPD

risperidone

Tablet 4 mg

Oral

Y

22.36

N

Y

22.36

18.52

17.17%

10%

GWAPD

sitagliptin

Tablet 100 mg

Oral

N

-

-

-

28.43

22.93

19.35%

10%

OWAPD

sitagliptin

Tablet 25 mg

Oral

N

-

-

-

28.43

22.93

19.35%

10%

OWAPD

sitagliptin

Tablet 50 mg

Oral

N

-

-

-

28.43

22.93

19.35%

10%

OWAPD

sunitinib

Capsule 12.5 mg

Oral

N

-

-

-

707.27

581.73

17.75%

10%

OWAPD

sunitinib

Capsule 25 mg

Oral

N

-

-

-

1423.46

1170.8

17.75%

10%

OWAPD

sunitinib

Capsule 37.5 mg

Oral

N

-

-

-

2133.39

1754.71

17.75%

10%

OWAPD

sunitinib

Capsule 50 mg

Oral

N

-

-

-

2882.07

2370.5

17.75%

10%

OWAPD

tacrolimus

Capsule 0.75 mg

Oral

Y

147.64

Y

Y

147.64

98.08

33.57%

30%

GWAPD

tamoxifen

Tablet 20 mg (as citrate)

Oral

Y

6.27

N

Y

6.27

4.97

20.73%

10%

GWAPD

temozolomide

Capsule 100 mg

Oral

Y

81.63

N

Y

81.63

59.7

26.87%

10%

GWAPD

temozolomide

Capsule 140 mg

Oral

Y

112.58

N

Y

112.58

82.33

26.87%

10%

GWAPD

temozolomide

Capsule 180 mg

Oral

Y

136.33

N

Y

136.33

99.7

26.87%

10%

GWAPD

temozolomide

Capsule 20 mg

Oral

Y

19.05

N

Y

19.05

13.93

26.88%

10%

GWAPD

temozolomide

Capsule 250 mg

Oral

Y

193.95

N

Y

193.95

141.84

26.87%

10%

GWAPD

temozolomide

Capsule 5 mg

Oral

Y

6.48

N

Y

6.48

4.74

26.85%

10%

GWAPD

tenofovir with emtricitabine

Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg

Oral

Y

23.4

N

Y

23.4

16.55

29.27%

10%

OWAPD

tenofovir with emtricitabine

Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg

Oral

Y

23.4

N

Y

23.4

16.55

29.27%

10%

OWAPD

tenofovir with emtricitabine

Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg

Oral

Y

23.4

N

Y

23.4

16.55

29.27%

10%

OWAPD

tenofovir with emtricitabine

Tablet containing tenofovir disoproxil succinate 301 mg with emtricitabine 200 mg

Oral

Y

23.4

N

Y

23.4

16.55

29.27%

10%

OWAPD

topiramate

Tablet 100 mg

Oral

Y

12.6

N

Y

12.6

9.72

22.86%

10%

GWAPD

topiramate

Tablet 200 mg

Oral

Y

21.17

N

Y

21.17

16.34

22.82%

10%

GWAPD

topiramate

Tablet 25 mg

Oral

Y

4.88

N

Y

4.88

4

22.75%

10%

GWAPD

topiramate

Tablet 50 mg

Oral

Y

8.01

N

Y

8.01

6.18

22.85%

10%

GWAPD

valproic acid

Tablet (enteric coated) containing sodium valproate 200 mg

Oral

Y

4.63

N

Y

4.63

4

18.57%

10%

GWAPD

valproic acid

Tablet (enteric coated) containing sodium valproate 500 mg

Oral

Y

9.17

N

Y

9.17

7.47

18.54%

10%

GWAPD

vancomycin

Capsule 125 mg (125,000 I.U.) (as hydrochloride)

Oral

N

-

-

-

66.21

50.69

23.44%

10%

GWAPD

vancomycin

Capsule 250 mg (250,000 I.U.) (as hydrochloride)

Oral

N

-

-

-

132.39

101.36

23.44%

10%

GWAPD

zoledronic acid

Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL

Injection

Y

70

N

Y

70

59.56

14.91%

10%

GWAPD

zoledronic acid

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

Injection

Y

67.26

N

Y

67.26

57.23

14.91%

10%

GWAPD

A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 April 2024 is available in the 2024 April Combination Flow-on Reductions from Price Disclosure Summary (Excel 13 KB). Sponsors were able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.

Indicative prices of brands scheduled for a price disclosure reduction

The dispensed prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.

Indicative prices are not published for any medicines that are:

  • not taking a price disclosure reduction in this cycle;
  • new brands after the date of publication;
  • brands with other price changes on the reduction day.

The indicative prices reports have been replaced by the confirmed prices reports below.

Confirmed prices of brands scheduled for a price disclosure reduction

This report sets out the dispensed prices of brands scheduled for a price disclosure reduction.

The confirmed prices reports for the 2024 April cycle can be downloaded below:

 

Brand price reductions and savings to patients

This report sets out price reductions per brand and potential individual savings to non-concessional patients from 1 April 2024. This information is made available to assist patients with understanding how much they may save on their PBS medicines.

The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.

The brand price reductions report for the 2024 April cycle can be downloaded below.